Periadventitial angiopoietin-1 gene transfer induces angiogenesis in rabbit carotid arteries.
This study was performed to evaluate angiogenic responses of angiopoietin-1 (Ang1) in vivo after adenovirus-mediated gene transfer in the periadventitial space of the rabbit carotid arteries using a collar technique. Adenoviruses encoding LacZ and vascular endothelial growth factor (VEGF) receptor-1-Ig fusion protein (VEGF-R1-Ig) adenoviruses were used as controls. Increased neovessel formation was seen in adventitia of the Ang1 transduced arteries 7 days after the gene transfer. Neovessels in the Ang1 transduced arteries were large in size and well perfused. Ang1 binds to Tie2 (tyrosine kinase with immunoglobulin and epidermal growth factor homology domain) receptors, which were expressed in the endothelium of the neovessels. When VEGF-R1-Ig was used with Ang1, it resulted in a decrease in the number of neovessels, which implies that VEGF-A or some other VEGF-R1 ligand(s) play a crucial role in angiogenesis occurring in response to Ang1. There were no significant differences in the total number of capillaries in the adventitia of the VEGF-R1-Ig transduced arteries as compared to LacZ controls. Neointima formation was not increased in the Ang1 transduced arteries as compared to the controls. We conclude that in the periadventitial space Ang1 shows angiogenic activity and is a potentially useful factor for the induction of therapeutic vascular growth in vivo.
Bhardwaj
S
S
Department of Biotechnology and Molecular Medicine, A.I.Virtanen Institute for Molecular Sciences, University of Kuopio, Kuopio, Finland.
Roy
H
H
Kärpänen
T
T
He
Y
Y
Hi
Y
Y
Jauhiainen
S
S
Hedman
M
M
Alitalo
K
K
Ylä-Herttuala
S
S
D000256:Adenoviridae / Q000235:genetics; D042683:Angiopoietin-1 / Q000235:genetics*; D000818:Animals; D002339:Carotid Arteries; D015870:Gene Expression; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000008:administration & dosage / Q000627:therapeutic use; D007136:Immunoglobulins / Q000235:genetics; D007267:Injections; D018919:Neovascularization, Physiologic; D011817:Rabbits; D042787:Receptor, TIE-2 / Q000378:metabolism; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000235:genetics; D014161:Transduction, Genetic / Q000379:methods*; D019076:Transgenes; D017539:Tunica Intima / Q000502:physiology; D040281:Vascular Endothelial Growth Factor Receptor-1 / Q000235:genetics
D042683:Angiopoietin-1; D007136:Immunoglobulins; D011993:Recombinant Fusion Proteins; D042787:Receptor, TIE-2; D040281:Vascular Endothelial Growth Factor Receptor-1